In a patient with an estimated glomerular filtration rate of 33 mL/min/1.73 m² (impaired renal function), which antidiabetic medication can be safely prescribed?

Antidiabetic Medications Safe at eGFR 33 mL/min/1.73 m²

At an eGFR of 33 mL/min/1.73 m², you should use metformin at a reduced dose (maximum 1000 mg daily) combined with an SGLT-2 inhibitor as first-line therapy, with GLP-1 receptor agonists as the preferred third agent if additional glycemic control is needed. 1

First-Line Therapy

Metformin

• Safe and recommended at eGFR 30-44 mL/min/1.73 m² with dose adjustment 1
• Maximum dose: 1000 mg daily (halve the usual dose) 1
• Monitor eGFR every 3-6 months at this level of kidney function 1
• Stop metformin if eGFR drops below 30 mL/min/1.73 m² 1
• Monitor for vitamin B12 deficiency with long-term use (>4 years) 1

SGLT-2 Inhibitors

• Strongly recommended for patients with eGFR 30-44 mL/min/1.73 m² 1
• Provide cardiovascular and renal protection independent of glucose-lowering effects 2, 1
• The 2024 BMJ guideline demonstrates high certainty evidence for survival benefit and reduced kidney failure risk at this eGFR level 2
• Most SGLT-2 inhibitors can be initiated down to eGFR 20-25 mL/min/1.73 m² depending on the specific agent 3
• Glucose-lowering efficacy decreases with lower eGFR, but cardiorenal benefits persist 3, 4

Additional Therapy for Glycemic Control

GLP-1 Receptor Agonists (Preferred)

If metformin and SGLT-2 inhibitor are insufficient for glycemic targets, add a long-acting GLP-1 RA 1

Safe options at eGFR 33:

• Dulaglutide: No dose adjustment needed, safe down to eGFR >15 mL/min/1.73 m² 1
• Liraglutide: No dose adjustment needed 1
• Semaglutide: No dose adjustment needed 1
• Exenatide immediate-release: Safe with CrCl >30 mL/min 1

Avoid exenatide extended-release (requires eGFR >45 mL/min/1.73 m²) 1

Start with low doses and titrate slowly to minimize gastrointestinal side effects 1

Alternative Agents

If GLP-1 RAs are not suitable, consider:

DPP-4 Inhibitors (require dose adjustment):

• Safe at eGFR 30-44 mL/min/1.73 m² with appropriate dose reduction 1
• Less preferred than GLP-1 RAs due to lack of cardiovascular benefits 1

Insulin:

• Safe at all levels of kidney function 1
• May require dose reduction as kidney function declines (reduced insulin clearance) 1

Sulfonylureas:

• Use with caution; increased hypoglycemia risk with renal impairment 1
• Prefer shorter-acting agents if used 1

Thiazolidinediones (TZDs):

• No dose adjustment needed 1
• Caution with fluid retention and heart failure risk 1

Critical Pitfalls to Avoid

1. Do NOT use metformin at full dose - must reduce to ≤1000 mg daily at this eGFR 1
2. Do NOT withhold SGLT-2 inhibitors - the 2022 KDIGO guideline emphasizes their benefit specifically at eGFR 30-44 mL/min/1.73 m² for cardiorenal protection 1
3. Do NOT use serum creatinine alone to assess kidney function - always use eGFR equations 5, 6, 7
4. Monitor eGFR closely (every 3-6 months) as medications may need adjustment if kidney function declines further 1
5. Hold metformin 48 hours before and after iodinated contrast procedures if eGFR <60 mL/min/1.73 m² 5

Treatment Algorithm Summary

At eGFR 33 mL/min/1.73 m²:

1. Start or continue metformin at reduced dose (≤1000 mg daily)
2. Add SGLT-2 inhibitor for cardiorenal protection
3. If additional glycemic control needed: Add long-acting GLP-1 RA (dulaglutide, liraglutide, or semaglutide preferred)
4. If GLP-1 RA unsuitable: Consider dose-adjusted DPP-4 inhibitor, insulin, or cautiously sulfonylurea
5. Monitor eGFR every 3-6 months and adjust medications accordingly

The KDIGO 2022 guideline emphasizes that most patients with T2D, CKD, and eGFR ≥30 mL/min/1.73 m² benefit from combination therapy with both metformin and SGLT-2 inhibitor 1, making this the cornerstone of management at eGFR 33.